Explore the role of patient-derived biology in enhancing antibody-drug conjugates for more effective cancer treatment.
Q4 2025 Earnings Call Transcript December 18, 2025 FuelCell Energy, Inc. beats earnings expectations. Reported EPS is $-0.83, expectations were $-0.97. Operator: Hello. And welcome to the FuelCell ...
Thank you, operator. This morning, FuelCell Energy released our financial results for the fourth quarter and fiscal year 2025 ...
Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has ...
Garlic mouthwash is emerging as a natural alternative to chemical rinses, offering potent antimicrobial benefits. Research ...
Abstract: This paper investigates the stability of a delayed load frequency control (LFC) power system. Firstly, a dynamic LFC model is reconstructed to facilitate the development of a suitable ...
Abstract: Durability, reliability, and efficiency remain the primary barriers that impede the commercialization of proton exchange membrane (PEM) fuel cells. Prognostics and health management (PHM) is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback